- Design
- Systematic review and meta-analysis of 63 observational studies
- Population
- 5852 ABO-incompatible vs 47,950 ABO-compatible kidney recipients
- Primary outcome
- Patient and graft survival, rejection, complications
- Effect
- Rejection RR 1.28 (1.17–1.40); AMR RR 2.14 (1.48–3.09)
This meta-analysis pooled 63 observational cohort and registry studies from 2010 to 2024, comparing 5852 ABO-incompatible with 47,950 ABO-compatible kidney transplant recipients. It was published in Urology Journal on 20 September.
ABO-incompatible transplantation was associated with more overall rejection (RR 1.28, 95% CI 1.17 to 1.40) and more antibody-mediated rejection (RR 2.14, 1.48 to 3.09), but not more T-cell-mediated rejection (RR 0.86, 0.72 to 1.04). Patient and graft survival at 1, 3 and 10 years were broadly similar, though 5-year patient survival favoured compatible transplants (RR 1.62, 1.13 to 2.32). Surgical complications and postoperative bleeding were markedly higher.
For living-donor programmes, including many in India where deceased-donor supply is limited, ABO-incompatible transplantation expands access with survival that is broadly comparable. The costs are early: bleeding, infection and antibody-mediated rejection, which need planning and surveillance.
- Counsel ABO-incompatible recipients about higher early rejection and bleeding risks.
- Plan desensitisation, titre monitoring and a low threshold for biopsy.
- Consider paired kidney exchange as an alternative where available.
- Monitor closely for antibody-mediated rejection in the first year.
Why it matters
It quantifies the trade-off for living-donor pairs who are blood-group incompatible.
Don't overread it
This is pooled observational data; the isolated 5-year survival difference is inconsistent with other time points.
The statistics, in plain English
All included studies were observational, so recipients differed in ways the pooled estimates cannot fully adjust for. The 5-year survival signal is not seen at 10 years, which suggests it may reflect differences between studies rather than a consistent effect.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for nephrology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free